TIF Click here for additional data file. References 1. Hamilton JB. Patterned loos of hair in man: types and incidence. Annals of the New York Academy of Sciences. The psychosocial impact of hair loss among men: a multinational European study. Current Medical Research and Opinion. Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. British Journal of Dermatology.
Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer. European Journal of Cancer. American Journal of Epidemiology. Journal of Clinical Oncology. Trieu N, Eslick GD. Alopecia and its association with coronary heart disease and cardiovascular risk factors: A meta-analysis.
International Journal of Cardiology. Male-pattern baldness susceptibility locus at 20p Nat Genet. Genetic Basis of Male Pattern Baldness. Journal of Investigative Dermatology. Prediction of male-pattern baldness from genotypes.
Eur J Hum Genet. Detection and interpretation of shared genetic influences on 42 human traits. Hunting the genes in male-pattern alopecia: how important are they, how close are we and what will they tell us? Experimental Dermatology. Evidence for a polygenic contribution to androgenetic alopecia. PLoS Med.
FGF5 as a regulator of the hair growth cycle: Evidence from targeted and spontaneous mutations. A genome-wide association scan in admixed Latin Americans identifies loci influencing facial and scalp hair features. Nature Communications. Sorokin AV, Chen J. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene.
Human Molecular Genetics. The role of tau MAPT in frontotemporal dementia and related tauopathies. Human Mutation. Susceptibility variants on chromosome 7p Oligophrenin-1 encodes a rhoGAP protein involved in X-linked mental retardation. PLoS Biol. The American Journal of Human Genetics. FGF5 is a crucial regulator of hair length in humans.
Proceedings of the National Academy of Sciences. Developmental Cell. Potocki—shaffer deletion encompassing ALX4 in a patient with frontonasal dysplasia phenotype. Orii N, Ganapathiraju MK. Regulation of cell proliferation and differentiation in the kidney. Frontiers in bioscience Landmark edition. Epidemiologic and genetic characteristics of alopecia areata part 2.
Acta Dermatovenerol Alp Pannonica Adriat. Mol Psychiatry. Genetic Epidemiology. Norwood OT. Male pattern baldness: classification and incidence. South Med J. A new multipoint method for genome-wide association studies by imputation of genotypes. Purcell S, Chang CC. PLINK v1. The Genomes Project Consortium. An integrated map of genetic variation from 1, human genomes. PLoS Comput Biol. Biological interpretation of genome-wide association studies using predicted gene functions.
R Core Team. R: A language and environment for statistical computing. BMC Bioinformatics. Common SNPs explain a large proportion of the heritability for human height. MPB is a good example of this. Scientists can determine how many MPB associated DNA variants a person has, and use them to estimate their likelihood of experiencing hair loss.
This kind of analysis—where multiple genetic variants are taken into consideration—is common in genetics and helps strengthen the predictive ability of some types of genetic tests. You might just be the next Samuel L. Markus M. PLoS Genetics We are a personal genomics company with a simple but powerful mission: empower every person to improve their life through DNA. December 11, The genetics of baldness: More complex than you might think.
Login ». As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Thanks for visiting. Don't miss your FREE gift. Sign up to get tips for living a healthy lifestyle, with ways to fight inflammation and improve cognitive health , plus the latest advances in preventative medicine, diet and exercise , pain relief, blood pressure and cholesterol management, and more. Get helpful tips and guidance for everything from fighting inflammation to finding the best diets for weight loss Stay on top of latest health news from Harvard Medical School.
Treatment is not usually necessary. However, hair loss that occurs rapidly or early in life can be distressing. If you wish to slow or stop the progression of hair loss, there are treatments available. Hair loss that is caused by a temporary situation such as illness, medication, stress or insufficient iron will stop when the cause is resolved.
Read more about abnormal hair loss. Finasteride and minoxidil are the main medicines currently available to treat hair loss.
However, they are not subsidised in New Zealand, so you need to pay for them yourselves. Medicines that are used to treat hair loss provide different results for different people. It's also not possible to predict who may or may not benefit from treatment. This is a prescription-only treatment for hereditary hair loss in men. It is available as a tablet. It works by blocking the conversion of testosterone to dihydrotestosterone.
The hair follicles then are not affected by this hormone and will not shrink. Treatment needs to be continued for at least 6 months once started. If successful, the treatment is continued to maintain the effect. Talk to your doctor to find out whether finasteride is suitable for you. Women should not take finasteride as a treatment for hair loss. Hair clinics may arrange prescriptions for both local and oral treatments. Read more about finasteride. Minoxidil is a rub-on treatment that can be bought from your local pharmacy.
It can be used by both men and women.
0コメント